Free Trial
NASDAQ:ENTA

Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

Enanta Pharmaceuticals logo
$6.37 +0.09 (+1.43%)
(As of 12/23/2024 05:45 PM ET)

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Key Stats

Today's Range
$6.11
$6.45
50-Day Range
$5.85
$13.00
52-Week Range
$5.70
$17.80
Volume
361,170 shs
Average Volume
225,073 shs
Market Capitalization
$135.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.50
Consensus Rating
Moderate Buy

Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
84th Percentile Overall Score

ENTA MarketRank™: 

Enanta Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 239th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Enanta Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Enanta Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($4.73) to ($4.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enanta Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enanta Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enanta Pharmaceuticals has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    16.38% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently decreased by 4.44%, indicating that investor sentiment is improving.
  • Dividend Yield

    Enanta Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Enanta Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.38% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently decreased by 4.44%, indicating that investor sentiment is improving.
  • News Sentiment

    Enanta Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • Search Interest

    1 people have searched for ENTA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,846.00 in company stock.

  • Percentage Held by Insiders

    13.64% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enanta Pharmaceuticals' insider trading history.
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

A.I. Trading System Helps Some Traders Pocket $1,100 per DAY!

What if I told you 60 seconds a day could completely change your life?

This AI-powered trading system finds high-probability option trades in less than 60 seconds a day

FY2025 Earnings Forecast for ENTA Issued By Leerink Partnrs
Evercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals (ENTA) Gets a Hold from Oppenheimer
See More Headlines

ENTA Stock Analysis - Frequently Asked Questions

Enanta Pharmaceuticals' stock was trading at $9.41 at the start of the year. Since then, ENTA stock has decreased by 32.3% and is now trading at $6.37.
View the best growth stocks for 2024 here
.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its earnings results on Monday, November, 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by $0.20. The business's revenue was down 22.8% on a year-over-year basis.

Top institutional shareholders of Enanta Pharmaceuticals include Krensavage Asset Management LLC (7.07%), Geode Capital Management LLC (2.25%), State Street Corp (2.12%) and Caligan Partners LP (1.52%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Nathalie Adda, Tara Lynn Kieffer, Scott T Rottinghaus and Terry Vance.
View institutional ownership trends
.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/25/2024
Today
12/24/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTA
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.50
High Stock Price Target
$27.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+206.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-116,040,000.00
Net Margins
-171.57%
Pretax Margin
-174.15%

Debt

Sales & Book Value

Annual Sales
$67.64 million
Book Value
$6.08 per share

Miscellaneous

Free Float
18,303,000
Market Cap
$135.01 million
Optionable
Optionable
Beta
0.49

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ENTA) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners